Purpose: To prospectively evaluate the long term cardiac effects of high-dose epirubicin and cyclophosphamide given to women with early stage, poor prognosis breast cancer.
Introduction
Despite adjuvant chemotherapy, women with extensive nodal involvement with breast cancer or large primary tumors have a poor prognosis [1] [2] [3] . Approximately 70%-90% of patients with more than 10 nodes involved will relapse within 10 years [4, 5] . Notwithstanding the caveats of patients selection and early reporting [6] , encouraging results have been observed in phase two studies utilizing high-dose chemotherapy (HDC) and hematopoietic stem cell transplant in this high-risk group [7] [8] [9] [10] [11] .
While the major acute toxicities of HDC can now be largely overcome with hematological growth factors, stem cell infusion and appropriate supportive care, prevention of long-term effects remains a challenge. One of the most debilitating late toxicities is cardiac failure. This is of special concern with the use of highdose anthracyclines and/or cyclophosphamide. Although anthracyclines cause cardiac damage related to the cumulative dose delivered [12] , it is unknown whether single large doses are more likely to cause myocardial damage than standard doses. In addition, while cardiac failure related to standard doses of doxorubicin or epirubicin usually becomes apparent four to eight weeks after the last dose or during treatment, occasionally it can occur some years later [13] .
We previously reported the feasibility of delivering multiple cycles of high-dose epirubicin and cyclophosphamide with peripheral blood progenitor cells support as treatment for women with early stage, poor prognosis breast cancer [14, 15] . Epirubicin was chosen because of its activity and dose-response in breast cancer [16] [17] [18] , and its more favorable toxicity profile compared with doxorubicin [19] . Moreover, randomized trials [20] [21] [22] [23] suggest that in early stage breast cancer anthracyclinecontaining adjuvant chemotherapy results in a higher disease-free and overall survival than non-anthracyclinecontaining regimens. There are few reports of prospective evaluation of the late cardiac effects of anthracyclinebased adjuvant therapy. Because data about early and late cardiotoxic effects of high-dose anthacyclines are also limited, we evaluated the cardiac function of the women in the current study after each cycle of chemotherapy and during subsequent follow-up.
Patients and methods

Eligibility and evaluation
Eligible patients were aged between 18 and 60 years with histologically confirmed poor prognosis breast cancer, defined as: stage 2 disease with 10 or more positive axillary nodes, or an estrogen-receptor negative tumor with at least four positive axillary nodes, or stage 3 disease. Staging procedures included complete blood count, liver function tests, chest X-ray, bone scan, liver ultrasound or computer tomography scan, and bone marrow aspirate and trephine. Patients were required to have a resting left ventricular ejection fraction (LVEF) of 50% or greater as measured by radionuclide (MUGA) scan. Women receiving adjuvant therapy commenced treatment on protocol within eight weeks of surgery.
Treatment
Mobilization of progenitor cells
Prior to chemotherapy, all patients received filgrastim (Amgen, Thousand Oaks, CA, USA) with or without recombinant human stem cell factor (Amgen, Thousand Oaks, CA, USA) [15] to mobilize progenitor cells as described elsewhere. Apheresis was performed on the fifth, sixth and seventh days [14, 24] . The product from each apheresis specimen was concentrated and cryopreserved.
Chemotherapy
High-dose chemotherapy consisted of epirubicin (Pharmacia-Upjohn, Milan, Italy) 200 mg/m 2 intravenously over 12 hours on day -4 and cyclophosphamide (Pharmacia-Upjohn, Milan, Italy) 4 gm/m 2 on day -3, given as I gm/m 2 intravenously over 30 minutes in four divided doses with MESNA (2-mercaptoethane sodium sulphonate) uroprotection. One third of each daily apheresis product was infused on day 0. Filgrastim (5 ug/kg daily by subcutaneous injection) and broadspectrum antibiotics were administered from day +1 until the time of granulocyte recovery. Three cycles of chemotherapy were delivered. The patients were participating in a feasibility study of this regimen, and while one cohort was treated at planned 28 day (n = 79) intervals, another was treated at 21 day intervals (n = 20) in order to increase dose-intensity.
Radiotherapy after chemotherapy was not mandated by the protocol, and was carried out according to institutional policy. Fifty patients received radiotherapy after completion of chemotherapy to the chest wall after mastectomy (n = 20), to the residual breast after breast conserving surgery (n = 18) or when there was no prior surgery (n = 12). Twenty-five patients had radiotherapy to the left side.
Cardiac function was evaluated by clinical assessment and measurement of cardiac ejection fraction. Patients were assessed clinically for evidence of cardiac failure and relapse of disease at least three times yearly after completion of treatment. Cardiac ejection fraction was assessed by radionuclide scan before therapy, after each cycle of chemotherapy, three months and six months after completion of chemotherapy, and yearly thereafter until disease relapse. Only two sites routinely carried out scans three months after treatment.
Statistics
Calculations were performed using SigmaStat (Jandel Software, San Rafael, CA, USA). All statistical analyses were conducted at the 0.05 level of significance and were two sided. Differences in LVEF with time and the changes in LVEF were assessed using one way repeated measures of analysis of variance (one way RM ANOVA). The influence of radiotherapy to the chest on changes in LVEF was assessed using Student's (-test. Likewise, comparisons of LVEF between patients who received chemotherapy every four weeks and those treated every three weeks were made with Student's i-test. Box-plots were produced with GraphPad programs (Prism, GraphPad Software, San Diego, CA, USA).
Results
Ninety-nine patients were treated between July 1992 and November 1995 at six institutions. At entry into the trial, all patients had normal baseline clinical cardiac function, as assessed by clinical examination, chest X-ray and LVEF. The median age of was 43 years (range 24 to 60 years). Four patients had a history of hypertension and one had diabetes mellitus. Further details of patient characteristics are given elsewhere [25] . Ninety-two women received all three cycles of chemotherapy. The reasons for failing to complete protocol therapy were withdrawal of consent after one cycle (n = 1), severe haemorrhagic cystitis (n = 1), severe angioneurotic oedema during administration of MESNA (« = 1) and anaphylactoid reaction following cyclophosphamide (n = 1) during the second cycle, sufficient GM-CFC for only two cycles (n = 2), and death due to intracranial haemorrhage secondary to thrombocytopenia during the third cycle (n = 1). Eighty-three patients had measurement of LVEF after all three cycles of chemotherapy. There was a fall-off in the number of patients undergoing radionuclide scans over time. This resulted from patient non-compliance, geographical inaccessibility to a nuclear scanning facility, and cessation of cardiac monitoring once patients had relapsed. The number of patients in whom the breast cancer had not relapsed at the time of each assessment of LVEF, that is, the total population at risk, is shown in Table 1 . It should be noted that cardiac function continued to be assessed clinically in all patients at each review for disease status. The median relapsefree survival at 28 June 1998 was 39 months (11 to 68 months). Thirty-three patients relapsed during the follow-up period. Only three of these women had an abnormal scan at the final assessment, one of whom had established congestive heart failure (CHF) at the time.
The results of serial LVEF assessments are given in Table 1 and the Figure. There was a significant fall in LVEF from pre-treatment baseline value at all timepoints after the first cycle of chemotherapy (P < 0.001, one way RM ANOVA). There was no significant deterioration in LVEF from the third month after cessation of Table 1 . Cardiac function (mean ± 95% CI) as assessed by radionuclide scan during and after three cycles of high-dose epirubicin and cyclophosphamide. chemotherapy onward, although there was a lot of variation between individuals in the pattern of change. The change in LVEF from baseline did not significantly differ at measures taken at six months and those at three years, and most patients had stable cardiac function with further follow-up. Thirty-five of the 99 patients had at least one measure of LVEF that was below normal, and in 19 this was first recorded during the treatment cant differences between any groups at any individual time points. Follow-up at 48 months is not included because of the very small number of patients available for evaluation at this time. Abbreviation: NS -not significant.
period. Twenty of the 35 (56%) women subsequently had a normal LVEF on further follow up. Nine patients with a normal LVEF at the end of treatment experienced a sustained fall to below normal in the follow-up period. Thirty-one patients experienced a fall in LVEF of > 15% from baseline on at least one scan. There was no difference in the fall in LVEF in women who received radiotherapy to the left chest compared with those given radiotherapy to the right chest (P > 0.1, Student's z-test; Table 2 ). Similarly, there was no difference in the fall in LVEF between those women who did and those who did not receive radiotherapy (P > 0.24, Student's Mest; Table 2 ). The change in LVEF was also not different between the group given chemotherapy every three weeks and the group treated every four weeks (P > 0.2, Student's /-test).
One patient died of acute myocardial necrosis after the third cycle of chemotherapy. She was 47 years old and had no significant past medical history and her baseline LVEF was 57%. She experienced febrile neutropenia after the first two cycles of chemotherapy, but made an uncomplicated recovery from each episode and at no stage did she have any evidence of cardiac decompensation. Radionuclide scans were not performed after the first two cycles of chemotherapy. Two days after commencing the third cycle, her renal function was noted to have deteriorated and she developed gram negative septicemia. She then developed clinical and radiological evidence of biventricular cardiac failure. A resting LVEF five days after chemotherapy was 41%. She was treated with broad-spectrum antibiotics and diuretics, with an initial good symptomatic response. However, she subsequently developed worsening cardiac, pulmonary, renal and liver dysfunction. An echocardiogram performed 10 days after chemotherapy commenced showed global deterioration in cardiac function. She died 23 days after the initial clinical evidence of cardiac failure and an autopsy revealed generalized myocardial necrosis, consistent with acute damage secondary to cyclophosphamide and/or epirubicin.
Two patients developed evidence of cardiac failure in association with a marked fall in LVEF after completion of therapy and a third woman developed radiological signs of cardiac failure but was asymptomatic. At completion of chemotherapy, the LVEF was less than 50% in only one of these patients, although for the three patients it had fallen by 11%, 8% and 14%. One patient received radiotherapy to the left chest wall while the other two did not receive radiotherapy. The signs of cardiac failure were detected approximately two years after the third cycle of chemotherapy in all three patients. All patients initially responded to medical therapy with angiotensin-converting enzyme inhibitors, diuretics and/ or digoxin. However, one patient, in whom the LVEF fell to 23%, developed progressive CHF despite antifailure medication and died 44 months after diagnosis without evidence of relapse of breast cancer. One patient with a LVEF of 20% developed relapse of breast cancer and had no further radionuclide tests. The asymptomatic patient had recovery of her LVEF from 38% to 48% over the subsequent 12 months.
Discussion
If the administration of intensive chemotherapy prolongs survival of women with breast cancer, it will be important to understand the long-term consequences of such an approach. Late cardiotoxicity related to high-dose anthracycline and cyclophosphamide is one of the most serious anticipated effects. In a retrospective analysis of three randomized trials of patients treated with 'standarddose' adjuvant chemotherapy with or without doxorubicin and/or breast radiotherapy, Valagussa et al. reported a low incidence of cardiac toxicity [26] . At a median follow up of 6.7 years, 89% of 825 patients experienced no detectable adverse cardiac events, and 1.8% of patients developed CHF or ischemic heart disease. Only 0.2% died of treatment-related cardiac complications. Doxorubicin-related CHF developed in four (0.8%) patients, but three of these women also received left-sided breast irradiation concurrent with chemotherapy. As in the current study, estimation of the true risk of a cardiac event with time after exposure to anthracycline was difficult because many of the patients had a poor prognosis and were likely to die from recurrent disease prior to the onset of late cardiac effects. In the Valagussa study, women were monitored with serial electrocardiograms, which is an insensitive and non-specific method for detecting doxorubicin-related cardiotoxicity [27] . In contrast, the current study prospectively evaluated women with serial radionuclide scans and clinical assessment for up to five years after receiving treatment. It is the first report of such extensive evaluation of cardiac function in patients given adjuvant anthracycline chemotherapy.
Little is known of the late cardiac effects of doseintensive chemotherapy. In a multi-center Belgium study, 4% of women with breast cancer treated with adjuvant epirubicin 100 tng/m 2 plus cyclophosphamide 500 mg/m 2 experienced CHF, while this occurred in 0.4% given epirubicin 60 mg/m 2 [28] . De Graaf et al. reported on the cardiotoxicity of various high-dose chemotherapy regimens that were given to women with breast cancer after standard dose induction therapy [29] . All patients received radiotherapy either prior to or after HDC. The therapy consisted of an anthracycline-based induction regimen followed by a cyclophosphamide or mitoxantrone-based ablative regimen. The patients were assessed at least one year after treatment with clinical examination, ECG and radionuclide studies. Of the 27 evaluable patients, one developed clinical evidence of CHF and four had a sub-normal LVEF without clinical sequelae. This was a small study in which only 27 of the original cohort of 86 women had been followed for longer than 12 months. Therefore, this report represents a limited subgroup of those at risk from the treatment and the true incidence of cardiotoxicity cannot be accurately gauged.
One patient experienced acute myocardial necrosis, an uncommon but well recognized complication of both high-dose cyclophosphamide [30] and high-dose anthracycline [31] . The patient who died of this complication had no pre-existing cardiac risk factors and, although conflicting reports exist [32] , cyclophosphamide probably does not augment doxorubicin-induced cardiac damage [33] . In a heterogeneous group of 63 patients who underwent HDC with bone marrow transplantation, the incidence of acute myocarditis was 5% [30] . A single event in the current study of 99 patients was therefore not greater than might have been expected.
Two patients developed clinical evidence of chronic cardiac dysfunction, although 38% of women experienced at least one measure of LVEF that was below normal and 31% had at least one measure that was > 15% lower than the pretreatment value. While others have identified these characteristics as being predictive for the subsequent development of CHF [27, 34] , this has not so far been the case in the period of observation in our study. This may be due to the relatively modest follow-up period, although the majority of patients who develop CHF will show some evidence of cardiac dysfunction within 12 months of cessation of therapy [12, 27, 35] . In addition, measurement of left ventricular function does not identify patients who later develop significant cardiac dysfunction [36] and is not necessarily predictive of the clinical course of established CHF [37] . For example, resting radionuclide scans have been observed to remain abnormal for over two years after anthracycline therapy in asymptomatic patients [34] . In other patients, compensatory mechanisms may allow the maintenance of an apparently normal left ventricular ejection fraction until the changes of cardiomyopathy are well established [38] .
Radiotherapy to the left chest did not increase the risk of cardiac damage. While multivariate analysis has identified chest wall irradiation as an independent risk factor for anthracycline-induced cardiomyopathy [33] , efforts were made to limit the cardiac exposure of pa-tients in this study. In general, only the breast or chest wall, along with the supraclavicular nodes in some instances, were treated. Some institutions also employed CT scan-guided planning to ensure minimal inclusion of the heart in the radiotherapy field. Prior cardiac disease and hypertension have also been identified as potential risk factors for anthracyline-induced cardiomyopathy [12] but were not present in those patients in the current study who developed cardiac toxicity.
The intensity of follow up cardiac evaluation in this study has not been reported elsewhere. Generally, patients have only been followed once they developed an abnormal LVEFor evidence of cardiac dysfunction after anthracycline treatment, or after a high cumulative dose of anthracycline. The findings in the current study suggest that a fall in LVEF is common in women receiving high-dose epirubicin, that deterioration in LVEF is uncommon between three months and four years after completion of treatment, and that recovery in LVEF frequently occurs. Furthermore, consistent with previous reports [27, 39] , treatment with routine cardiac failure management successfully reversed symptoms and signs in two of the three patients who developed CHF.
The fall in the number of patients having a radionuclide scan means that it is not possible to make a true estimate of the medium to long term incidence of subclinical cardiotoxicity for the whole patient population. However, cardiac function as assessed clinically and by LVEF remained stable or improved after treatment in most patients that remained alive without disease. The detection of cardiac abnormalities in this study could have reflected the frequency of cardiac monitoring or the effect of administration of epirubicin at a high dose per cycle. An important caveat is that reports of late onset of anthracycline-induced cardiac toxicity [27, 40] indicate it is imperative that patients treated with this or similar regimens who remain alive continue to be assessed. Whether the incidence of clinical or radiological cardiac events in this study was higher than might be expected if the same total dose of epirubicin was given at lower doses is unclear, and such a determination can only be made in a randomized trial.
